01873nam a2200289Ia 4500001000700000003000600007005001700013008004100030010001500071020003100086020002800117035002100145040001000166050002700176245011100203260005400314300002500368500005100393504005100444505078800495650005701283650004401340650005101384650005401435700003601489710005801525288234OCoLC20160527201727.0070810s2007 vau b 000 0 eng d a2007033206 a9781570185762 (alk. paper) a157018576X (alk. paper) a(OCoLC)237292273 aPUCPR00aKF 2915 .P4bP495 200700aPharmaceutical lawbregulation of research, development, and marketingceditor-in-chief, Michael E. Clark. aArlington, VabBureau of National Affairscc2007. axlvi, 853 p.c26 cm. a"American Bar Association, Health Law Section" aIncludes bibliographical references and index.0 aStatutory and regulatory controls for drug development -- Key federal agencies regulating pharmaceuticals -- Federal regulation of advertising, promotion, and distribution practices -- Potential liability for drug companies, health care providers and insurers: off-label prescribing and internet advertising -- Federal regulation of clinical research -- Avoiding fraud and abuse penalties and sanctions -- Regulation of privacy under hipaa and other privacy laws -- Federal sentencing guidelines and compliance measures -- The FDA approval process for new drugs -- State regulatory schemes for pharmaceuticals and related issues -- Antitrust and intellectual law issues for pharmaceutical companies -- Securities law issues and disclosure considerations for pharmaceutical companies. 0aPharmacyxLaw and legislationzUnited States.2Local 0aDrug developmentzUnited States.2Local 0aPharmaceutical IndustryzUnited States.2Local 0aDrugsxLaw and legislationzUnited States.2Local1 aClark, Michael E.d1956-2Local2 aAmerican Bar Association.bHealth Law Section.2Local